Revance Therapeutics (STU:RTI) Days Sales Outstanding : 35.07 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Revance Therapeutics Days Sales Outstanding?

Revance Therapeutics's average Accounts Receivable for the three months ended in Dec. 2023 was €24.6 Mil. Revance Therapeutics's Revenue for the three months ended in Dec. 2023 was €64.0 Mil. Hence, Revance Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2023 was 35.07.

The historical rank and industry rank for Revance Therapeutics's Days Sales Outstanding or its related term are showing as below:

STU:RTI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.14 Med: 123.05 Max: 23861.99
Current: 30.21

During the past 13 years, Revance Therapeutics's highest Days Sales Outstanding was 23861.99. The lowest was 12.14. And the median was 123.05.

STU:RTI's Days Sales Outstanding is ranked better than
85.2% of 892 companies
in the Biotechnology industry
Industry Median: 72.245 vs STU:RTI: 30.21

Revance Therapeutics's Days Sales Outstanding increased from Dec. 2022 (21.84) to Dec. 2023 (35.07).

Revance Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Revance Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revance Therapeutics Days Sales Outstanding Chart

Revance Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

23,286.41

43.55

11.84

19.93

30.68

Revance Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															21.84	24.82	25.58	33.91	35.07

Competitive Comparison of Revance Therapeutics's Days Sales Outstanding

For the Biotechnology subindustry, Revance Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revance Therapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revance Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Revance Therapeutics's Days Sales Outstanding falls into.

Revance Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Revance Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (10.704	+	25.379)	/	2 )	/	214.615	*	365
=	18.0415					/	214.615	*	365
=	30.68

Revance Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (23.813	+	25.379)	/	2 )	/	64.006	*	365 / 4
=	24.596					/	64.006	*	365 / 4
=	35.07

Revance Therapeutics (STU:RTI) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Revance Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Revance Therapeutics (STU:RTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (STU:RTI) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

RVNC:USA

Address

1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203

Website

https://www.revance.com

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Revance Therapeutics (STU:RTI) Headlines

No Headlines